Hosted on MSN1h
CHOP doctors named 'Disruptors of the Year' for groundbreaking sickle cell gene therapyThe Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...
Every day, hospitals throughout the U.S. transfuse blood or blood components, such as platelets, to save the lives of people who are in car crashes, and victims of fires and other emergencies.
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
Simmie White is taking control of her own story. The six-year-old girl and her mother want others to understand more about ...
Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
The Urban League of Greater Madison and The American Red Cross will host a Sickle Cell Awareness Blood Drive on Saturday, Feb ...
An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.
The Apostolic Church of Jesus Christ held a Sickle Cell blood drive Saturday, to help those affected with the condition.
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback